Adjuvant Olaparib for Patients with <i>BRCA1</i> - or <i>BRCA2</i> -Mutated Breast Cancer

Guy's Hospital, King's College London, Breast Cancer Now, Harvard University, Dana-Farber Cancer Institute, Tel Aviv University, Sheba Medical Center, University of Milan, European Institute of Oncology, Breast International Group, UPMC Hillman Cancer Center, NRG Oncology, Frontier Science Foundation, Université Libre de Bruxelles, Institut Jules Bordet, AstraZeneca (Brazil), Hebron University, Vall d'Hebron Institute of Oncology, University of Pennsylvania, AstraZeneca (United Kingdom), National Cancer Institute, Sahlgrenska University Hospital, University of Gothenburg, University of Pittsburgh, Gdańsk Medical University, Kaiser Permanente Vallejo Medical Center, Fudan University Shanghai Cancer Center, Northside Hospital, Piedmont HealthCare, National Institute of Oncology, International Hereditary Cancer Center, Read-Gene (Poland), Pomeranian Medical University, University of Colorado Cancer Center, UCLA Jonsson Comprehensive Cancer Center, University of Colorado Denver, Goethe University Frankfurt, Cardiovascular Center Bethanien, German Breast group, Integrated Oncology (United States), University Hospital Cologne, Medical University of Vienna, NSABP Foundation, Merck & Co., Inc., Rahway, NJ, USA (United States), The University of Queensland, Houston Methodist, Cornell University